other material
confidence high
sentiment positive
materiality 0.70
Pasithea reports positive Phase 1 data for PAS-004: no TRAEs, prolonged stable disease in colon cancer patient
Pasithea Therapeutics Corp.
- No treatment-related adverse events or dose-limiting toxicities observed in first 2 cohorts (n=6); no rash or GI toxicity.
- Heavily pre-treated stage 3 colon cancer patient (BRAF K601E) achieved prolonged stable disease, remains on drug into 6th cycle.
- Half-life ~70 hours supports once-daily or less frequent oral dosing; steady-state Cmax/Cmin ratio of 1.2.
- Systemic exposure at steady-state enables constant target inhibition while avoiding peak plasma toxicities.
- Safety review completed; cohort 3 dosing initiated at 8 mg with protocol amendment to increase dosing schedule.